• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
GAO Yunxiang,FAN Yiwei,ZHU Yu,ZHAO Chengguang,ZHAO Haiyang.The application of FGFR inhibitors in prostate cancer[J].Journal Of Pharmaceutical Research,2024,43(5):466-472,479[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2759times   Download 3112次 QR Code for this article
Scan with your phone!
FGFR抑制剂在前列腺癌中的应用
高云香1,范一苇2,朱宇2,赵承光2,赵海洋1
Font:Larger+|Default|Smaller-
(1.温州大学生命科学研究院,浙江省生物医药协同创新中心,浙江 温州 325035;2.温州医科大学药学院,浙江 温州 325035)
摘要:
成纤维细胞生长因子受体(Fibroblast Growth Factor Receptor, FGFR)的异常表达或激活与肿瘤的发生发展密切相关,以FGFR为靶点小分子抑制剂成为近年来的研究热点。Erdafitinib作为首个被美国FDA批准的FGFR小分子抑制剂,已用于FGFR基因突变的晚期前列腺癌。处于临床试验阶段的多个FGFR抑制剂同样显示出了令人满意的治疗效果。本文就FGFR结构、FGFR信号通路、FGFR抑制剂以及其耐药模式进行综述,以期为FGFR抑制剂的前列腺癌临床应用提供参考。
关键词:  成纤维细胞生长因子受体抑制剂  前列腺癌  致癌信号  耐药
DOI:10.13506/j.cnki.jpr.2024.05.010
基金项目:浙江省自然科学基金(No.LY21H300005、LTGY23H160019)
Publication Date:May 25, 2024
The application of FGFR inhibitors in prostate cancer
GAO Yunxiang1,FAN Yiwei2,ZHU Yu2,ZHAO Chengguang2,ZHAO Haiyang1
(1. Institute of Life Sciences, Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou 325035, China; 2. School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China)
Abstract:
The abnormal expression or activation of fibroblast growth factor receptors (Fibroblast Growth Factor Receptor, FGFR) is closely related to the occurrence and development of tumors, and small molecule inhibitors targeting FGFRs have become a research hotspot in recent years. Erdafitinib, as the first FGFR small molecule inhibitor, has been approved by the US FDA for use in advanced prostate cancer with FGFR gene mutations. Multiple FGFR inhibitors in clinical trials have also shown satisfactory therapeutic effects. This article provides a review of FGFR structure, FGFR signaling pathway, FGFR inhibitors, and their drug resistance patterns, with the aim of providing reference for the clinical application of FGFR inhibitors in prostate cancer.
Key words:  FGFR inhibitors  Prostate cancer  Carcinogenic signals  Drug resistance
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.